Hydroxamic Acid Inhibitors for Botulinum Neurotoxin Light Chain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for botulinum neurotoxin (BoNT) exposure are ineffective in addressing the prolonged paralysis caused by BoNT/A, as they primarily target extracellular steps in intoxication, failing to inhibit the intraneuronal light chain (LC) activity, which persists and causes prolonged paralysis.
Innovation Solution
Development of hydroxamic acid compounds that act as inhibitors of the BoNT/A light chain, formulated into pharmaceutical compositions to be administered to subjects exposed to botulinum toxin, targeting the intraneuronal LC to halt or reverse the paralysis by inhibiting proteolytic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments targeting extracellular steps are used, then initial intoxication can be addressed, but intraneuronal light chain activity persists causing prolonged paralysis
Solution Approach 1:
The patent introduces a small molecule inhibitor as an intermediary substance that penetrates neuronal membranes to reach and inhibit the intraneuronal light chain of BoNT/A. This mediator bridges the gap between extracellular treatment administration and intracellular target engagement, enabling therapeutic action where previous treatments failed.
Solution Approach 2:
The invention changes the chemical parameters of the treatment by developing small molecule compounds with specific properties: sufficient lipophilicity to cross neuronal membranes, appropriate molecular size for penetration, and chemical structure capable of binding to the light chain active site. These parameter changes enable the treatment to reach and inhibit intraneuronal targets.
2Reliability
If treatments are designed to cross neuronal membranes to reach intraneuronal targets, then LC activity can be inhibited, but drug delivery complexity increases
Solution Approach 1:
The small molecule inhibitor is designed to self-deliver across the neuronal membrane without requiring complex delivery systems. The molecule's inherent lipophilic properties and appropriate size enable it to passively diffuse through the membrane barrier, eliminating the need for sophisticated delivery mechanisms while still achieving intraneuronal target engagement.
3Reliability
If small molecule inhibitors are developed to penetrate neuronal membranes, then intraneuronal LC can be inhibited, but drug development complexity increases
Solution Approach 1:
The drug development process focuses on optimizing specific molecular parameters: balancing lipophilicity for membrane penetration with hydrophilicity for solubility, adjusting molecular weight for penetration efficiency, and designing functional groups that specifically bind to the light chain. These targeted parameter optimizations streamline the development process while achieving the desired intraneuronal inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydroxamic acid compounds effectively inhibit BoNT/A LC activity, potentially slowing or halting the progression of intoxication and accelerating recovery from paralysis by restoring neurotransmitter secretion, offering a Type II efficacy profile by enhancing SNAP-25 turnover and restoring exocytosis function.
Implementation Method 1
The compounds disclosed herein are useful as inhibitors of botulinum neurotoxin (BoNT) light chains (LCs). In particular, the compounds disclosed herein can be used to treat exposure to BoNT/A... hydroxamic acid compounds that act as inhibitors of the BoNT/A light chain... inhibiting proteolytic activity
Data Source
AI summary
Compounds of formula I are provided:R1 is an alkoxy or O(CH2)pX, p is an integer from 2 to 3 and X is OH, NH2, or CO2H, m is an integer from 0 to 5, n is an integer from 0 to 5, each R2 is independently selected from hydrogen, alkenyl, hydroxyalkyl, alkoxymethyl, heterocyclyl, hetereocyclylmethyl, amino, amido, hydroxamido, any of which may be optionally substituted with one or more of acyl, alkyl, alkoxy, hydroxyalkyl, or halogen, each R3 is independently selected from hydrogen, halogen, alkyl, alkenyl, carboxy, hydroxymethyl, amido, and at least one of R2 and R3 is not hydrogen.